**Tide Pharmaceutical Acquires Hangzhou Land for Peptide API Production Base**
Tide Pharmaceutical (03880.HK) announced on September 24 it completed the acquisition of an industrial land parcel and buildings in Hangzhou's Qiantang District. The approximately 2-hectare site, with 13,500 square meters of existing factory space, will serve as Phase I of a scaled CDMO production base. The company plans to build large-scale peptide active pharmaceutical ingredient (API) production lines with a designed annual capacity of 3-5 tons. A future Phase II will integrate an adjacent 3.73-hectare plot, creating a total 5.73-hectare production park.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that Tide Pharma's land acquisition in Hangzhou's Qiantang district is a smart real estate move in a prime biotech hub.
- Both agree that the BIOSECURE Act creates a real opportunity for Chinese CDMOs like Tide to capture Western pharma contracts.
- Both acknowledge that the competitive landscape is crowded, with WuXi AppTec and others chasing the same peptide market.
Points of contention
- Eastern Agent sees the expansion as a long-term strategic move backed by China's industrial policy, while Neutral Agent views it as a speculative bet without confirmed customer contracts.
- Eastern Agent argues that government programs like 'Healthy China 2030' provide concrete demand signals, but Neutral Agent says these are vague policies, not purchase orders.
- Neutral Agent claims Chinese peptide CDMO capacity is already at 60-65% utilization, making a 15-20% increase risky, while Eastern Agent says building ahead of demand is standard in the CDMO industry.
Blind spots
- Both sides overlook the specific financial details of Tide's deal, like the cost of the land and how it's funded.
- Neither side discusses the potential impact of regulatory changes in China or the US on Tide's dual-market strategy.
- The debate ignores the role of smaller competitors or new entrants that could disrupt the peptide CDMO market.
WorldAttention’s read
Tide Pharma's land purchase in Hangzhou is a defensible move that secures valuable real estate in a growing biotech hub, but the big question remains unanswered: who will buy their peptide capacity? Eastern Agent frames it as a smart long-term bet backed by China's industrial policy and the BIOSECURE Act opportunity, while Neutral Agent sees it as a risky speculation in an already crowded market. Both sides agree the land itself is a good investment, but the success of the whole plan depends on Tide winning contracts against bigger players like WuXi AppTec. Until we see signed deals or actual production numbers, this is a calculated gamble, not a sure thing.
Reporting timeline
Tide Pharmaceutical Completes Acquisition of Hangzhou Land for Peptide Custom R&D Base
Tide Pharmaceutical (03880.HK) announced on September 24 that it has completed the acquisition of an industrial land parcel and buildings in the Qiantang District of Hangzhou, China, as part of its strategic capacity expansion for peptide and oligonucleotide custom research, development, and production (CDMO) services. The acquired site, covering approximately 30 mu (about 2 hectares) with 13,500 square meters of existing factory space, will serve as Phase I of the company's scaled custom R&D and production base. Tide plans to construct large-scale peptide active pharmaceutical ingredient (API) production lines on the site, with an annual design capacity of 3-5 tons. The company further intends to integrate an adjacent 56-mu plot in Phase II, creating a total R&D and production park spanning approximately 86 mu.
Read sourceTide Pharma Completes Acquisition of Industrial Land in Hangzhou for Peptide Production Base
Tide Pharmaceutical (03880.HK) announced on September 24 that it has completed the acquisition of an industrial land parcel and related properties in the Qiantang District of Hangzhou, China. The site, covering approximately 30 mu (about 2 hectares) with existing factory buildings of around 13,500 square meters, will serve as Phase I of the company's scaled custom research and production base for peptides and oligonucleotides. Tide Pharma plans to build a large-scale peptide active pharmaceutical ingredient (API) production line on the site, with an annual design capacity of 3-5 tons. The company also intends to integrate an adjacent 56-mu plot in the future, creating a total campus of about 86 mu for a comprehensive custom research and production park. This acquisition is part of Tide Pharma's strategic capacity layout to advance its peptide and oligonucleotide custom development and manufacturing business.
Read sourceTide Pharmaceutical Acquires Hangzhou Property for Phase I of Large-Scale CDMO Base
Tide Pharmaceutical (03880) announced the completion of an acquisition of an industrial land and property in the Qiantang District of Hangzhou, China, to serve as the Phase I project for its large-scale CDMO (Contract Development and Manufacturing Organization) production base. The site covers approximately 30 mu (about 2 hectares) with existing factory floor space of about 13,500 square meters. The company plans to build large-scale peptide active pharmaceutical ingredient (API) production lines on the site, with a designed annual capacity of 3-5 tons, subject to construction progress, equipment commissioning, regulatory approvals, and market demand. The company intends to further integrate an adjacent 56-mu plot for Phase II, creating a total 86-mu CDMO production park to expand capacity and enhance its ability to undertake large commercial projects. The board believes this expansion aligns with the company's peptide and oligonucleotide CDMO business needs and will benefit shareholders.
Read sourceShow 4 older updatesHide older updates
Tide Pharmaceutical Acquires Hangzhou Property for Phase 1 of Large-Scale CDMO Base
Tide Pharmaceutical (03880) announced via Zhitong Finance that it has completed the acquisition of an industrial land and property in the Qiantang District of Hangzhou, China, to serve as Phase 1 of its large-scale CDMO production base project. The site covers approximately 30 mu (about 2 hectares) with 13,500 square meters of existing factory space. The company plans to build large-scale peptide active pharmaceutical ingredient (API) production lines at the site, with a designed annual capacity of 3-5 tons, though actual output and commissioning will depend on construction progress, equipment commissioning, regulatory approvals, and market demand. The company intends to subsequently integrate an adjacent 56-mu plot to create a total 86-mu CDMO production park to further expand capacity and enhance its ability to undertake large commercial projects. The board believes this capacity expansion is necessary to support the group's peptide and oligonucleotide CDMO business development and will benefit shareholders.
Read sourceTide Pharma Buys Land in Hangzhou for Large-Scale Peptide API Production Line
Tide Pharmaceutical (03880.HK) announced on September 24 that it has completed the acquisition of an industrial land parcel and buildings in the Qiantang District of Hangzhou, China, as part of its strategic capacity expansion for its peptide and oligonucleotide CDMO business. The project, designated as Phase I of the company's scaled CDMO production base, covers approximately 30 mu (about 2 hectares) with existing factory floor space of about 13,500 square meters. Tide plans to build a large-scale peptide active pharmaceutical ingredient (API) production line on the site, with a designed annual capacity of 3-5 tons, though actual output and commissioning will depend on construction, equipment debugging, regulatory approvals, and market demand. The company intends to further integrate an adjacent 56-mu plot in Phase II to create a total 86-mu CDMO production park, aiming to expand capacity and enhance its ability to undertake large commercial projects. The board believes this expansion will support the group's CDMO business development and benefit shareholders.
Tide Pharma Acquires Industrial Land for Large-Scale Peptide CDMO Base in Hangzhou
On September 24, Tide Pharmaceutical (stock code 03880) announced the completion of an acquisition of an industrial land parcel and property in the Qiantang District of Hangzhou, China. The site will serve as the first phase of its large-scale peptide CDMO (Contract Development and Manufacturing Organization) production base. Phase one covers approximately 30 mu (about 2 hectares) of land, with existing factory floor space of around 13,500 square meters. The company expects to build an annual production capacity of 3 to 5 metric tons of peptide active pharmaceutical ingredients (APIs) at this facility. The announcement was sourced from Caizhongshe and reported via East Money's market updates.
Read sourceTide Pharma Completes Acquisition of Industrial Land in Hangzhou for Peptide Custom R&D Base
Tide Pharmaceutical (03880.HK) announced on September 24 that it has completed the acquisition of an industrial land parcel and existing buildings in the Qiantang District of Hangzhou, China, as part of its strategic capacity expansion for peptide and oligonucleotide custom development and manufacturing. The site covers approximately 30 mu (about 2 hectares) with existing factory floor space of about 13,500 square meters. The company plans to use the property as Phase I of a large-scale customized R&D and production base project, specifically for building a large-scale peptide active pharmaceutical ingredient (API) facility. The announcement was made via a voluntary filing to the Hong Kong Stock Exchange.
Read source